Universal Screening for Mismatch-Repair Deficiency in Endometrial Cancers to Identify Patients With Lynch Syndrome and Lynch-like Syndrome

Although consensus has yet to be reached on universal mismatch-repair (MMR) protein immunohistochemical (IHC) screening for Lynch syndrome (LS) in endometrial cancer (EC), an increasing number of institutions have adopted universal screening protocols similar to those used for colorectal carcinoma. Here we describe our institution's experience with a prospective universal screening protocol in which all ECs resected over a period of 19 months (n=242) were screened for MLH1, PMS2, MSH2, and MSH6 deficiencies using IHC, followed by MLH1 promoter methylation testing when appropriate. When consent was obtained, tumor samples underwent next-generation sequencing. A total of 11 unmethylated MMR-deficient cases (4.5% of cohort) were identified through IHC screening. Germline testing was performed in 10 cases and confirmed LS in 4 patients (1.7% of cohort). Of our 4 confirmed LS cases, 1 did not meet traditional LS screening criteria (eg, age below 50 y, Revised Bethesda criteria). In addition, universal screening identified 6 germline-negative MMR-deficient nonmethylated cases, 4 of which occurred in women older than 50. Although our next-generation sequencing data suggest somatic mutations in 4 of these cases, it is possible that these cases may represent cases of “Lynch-like syndrome.” We conclude that a subset of LS cases could be missed using traditional screening guidelines. The value of screening for Lynch-like syndrome has yet to be determined. Although the cost-effectiveness of universal screening in EC has yet to be elucidated, we conclude that universal IHC screening is currently a reasonable, and arguably superior, approach to screening for LS.

[1]  T. Longacre,et al.  Lynch Syndrome Screening in the Gynecologic Tract: Current State of the Art , 2016, The American journal of surgical pathology.

[2]  Lauren L. Ritterhouse,et al.  Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. , 2015, JAMA oncology.

[3]  F. Gao,et al.  Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Pai,et al.  Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome. , 2015, Human pathology.

[5]  C. Moskaluk,et al.  Clinicopathologic Comparison of Lynch Syndrome–associated and “Lynch-like” Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry , 2015, The American journal of surgical pathology.

[6]  F. Gao,et al.  Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. , 2015, Gynecologic oncology.

[7]  H. Mackay,et al.  Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing , 2014, Cancer.

[8]  W. Frankel,et al.  Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. , 2014, Gastroenterology.

[9]  W. Hahn,et al.  BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers , 2014, Nucleic acids research.

[10]  R. Pai,et al.  Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer , 2014, The American journal of surgical pathology.

[11]  Q. Long,et al.  Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families. , 2014, International journal of clinical and experimental pathology.

[12]  R. Broaddus,et al.  Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome. , 2014, Gynecologic oncology.

[13]  A. Karnezis,et al.  Association of Tumor Morphology With Mismatch-repair Protein Status in Older Endometrial Cancer Patients: Implications for Universal Versus Selective Screening Strategies for Lynch Syndrome , 2014, The American journal of surgical pathology.

[14]  J. Carethers.  Differentiating Lynch-like from Lynch syndrome. , 2014, Gastroenterology.

[15]  I. Nagtegaal,et al.  Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. , 2014, Gastroenterology.

[16]  Alexander M. Metcalf,et al.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F. Aranda,et al.  Prevalence of Lynch Syndrome among Patients with Newly Diagnosed Endometrial Cancers , 2013, PloS one.

[18]  C. Eng,et al.  Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center. , 2013, Gynecologic oncology.

[19]  Á. Carracedo,et al.  Risk of cancer in cases of suspected lynch syndrome without germline mutation. , 2013, Gastroenterology.

[20]  B. Clarke,et al.  Identifying Lynch Syndrome in Patients With Endometrial Carcinoma: Shortcomings of Morphologic and Clinical Schemas , 2012, Advances in anatomic pathology.

[21]  E. Steyerberg,et al.  Comparison of the clinical prediction model PREMM1,2,6 and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer , 2012, Gut.

[22]  B. Clarke,et al.  Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation‐positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries , 2012, Cancer.

[23]  A. Gill,et al.  Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma , 2010, Pathology.

[24]  C. Boland,et al.  Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. , 2010, Gastroenterology.

[25]  Laura H. Tang,et al.  Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome: A 2-antibody Panel May be as Predictive as a 4-antibody Panel , 2009, The American journal of surgical pathology.

[26]  H T Lynch,et al.  Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications , 2009, Clinical genetics.

[27]  K. Kosarin,et al.  Selection of Endometrial Carcinomas for DNA Mismatch Repair Protein Immunohistochemistry Using Patient Age and Tumor Morphology Enhances Detection of Mismatch Repair Abnormalities , 2009, The American journal of surgical pathology.

[28]  J. Kwon,et al.  Cost‐effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome , 2008, Cancer.

[29]  A. Spurdle,et al.  Molecular, Pathologic, and Clinical Features of Early-Onset Endometrial Cancer: Identifying Presumptive Lynch Syndrome Patients , 2008, Clinical Cancer Research.

[30]  Eero Pukkala,et al.  Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. , 2005, Gastroenterology.

[31]  R. Broaddus,et al.  Gynecologic Cancer as a “Sentinel Cancer” for Women With Hereditary Nonpolyposis Colorectal Cancer Syndrome , 2005, Obstetrics and gynecology.

[32]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[33]  J. Inazawa,et al.  Unfavorable prognostic factors associated with high frequency of microsatellite instability and comparative genomic hybridization analysis in endometrial cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  R. Scully,et al.  Unusual Epithelial and Stromal Changes in Myoinvasive Endometrioid Adenocarcinoma: A Study of Their Frequency, Associated Diagnostic Problems, and Prognostic Significance , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[35]  J. Lutterbaugh,et al.  Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. , 2001, Cancer research.

[36]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[37]  L. Aaltonen,et al.  Cancer risk in mutation carriers of DNA‐mismatch‐repair genes , 1999, International journal of cancer.

[38]  K. Lu,et al.  One size may not fit all: the debate of universal tumor testing for Lynch syndrome. , 2015, Gynecologic oncology.

[39]  J. Stockman.  Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome , 2013 .

[40]  Nikhil Wagle,et al.  High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.

[41]  Ewout W Steyerberg,et al.  The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. , 2011, Gastroenterology.

[42]  E. Steyerberg,et al.  Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. , 2008, Gastroenterology.

[43]  J. Stockman,et al.  Prediction of MLH1 and MSH2 Mutations in Lynch Syndrome , 2008 .

[44]  R. Broaddus,et al.  Pathologic features of endometrial carcinoma associated with HNPCC , 2006, Cancer.

[45]  J. Stockman.  Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) , 2006 .

[46]  A D Carothers,et al.  Cancer risk associated with germline DNA mismatch repair gene mutations. , 1997, Human molecular genetics.

[47]  Jeffrey R. Botkin,et al.  Summary of Recommendations: The Evaluation of Genomic Applications , 2022 .